Mary Jessel, SVP of Global Medical Affairs at Telix, discusses the potential of precision medicine in oncology and the importance of targeted drug delivery and personalized dosimetry. She shares her background and career moves, emphasizing the importance of finding passion and planning for the future. Mary also provides leadership advice, focusing on strengths and empowering others. She highlights the significance of putting people and culture first in organizations. The conversation explores setbacks and learning from failures, as well as future advancements and trends in radiopharmaceuticals. Finally, Mary discusses the challenges and obstacles in radio pharma development and adoption.
Understanding Telix, page-496
-
- There are more pages in this discussion • 1,177 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$22.41 |
Change
0.210(0.95%) |
Mkt cap ! $7.500B | |||
| Open | High | Low | Value | Volume |
| $22.00 | $22.45 | $21.83 | $18.92M | 849.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2587 | $22.29 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $22.43 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/11/2024 (20 minute delay) ? |
| TLX (ASX) Chart |